Tagged with Niche

China Pharma News: Eisai/Bliss Biopharma USD 2 Billion Partnership; Hasten Biopharmaceutic/Roche Deal

China China Pharma News: Eisai/Bliss Biopharma USD 2 Billion Partnership; Hasten Biopharmaceutic/Roche Deal

China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre. COVID global emergency over but risks remain, says China health official (Reuters)…

Interview: Shahbaz Ardalan – Managing Director, Alpex Pharma, Switzerland

Switzerland Interview: Shahbaz Ardalan – Managing Director, Alpex Pharma, Switzerland

Switzerland Alpex Pharma is a specialized manufacturer of niche oral delivery forms, both for third parties and for their own portfolio of products for out-licensing. Managing Director Shahbaz Ardalan discusses the firm’s heritage, commitment to quality, and his plans for Alpex’s expansion. Alpex is highly specialized in a few key dosage…

Interview: Piero Poli – President & CEO, Rivopharm, Switzerland

Switzerland Interview: Piero Poli – President & CEO, Rivopharm, Switzerland

Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…

Interview: Paolo Andreatta – CEO, E-Pharma Trento, Italy

Pharma Interview: Paolo Andreatta – CEO, E-Pharma Trento, Italy

Pharma E-Pharma Trento is a pharmaceutical company specialized in development and production of niche oral delivery forms, such as soluble, effervescent, chewable and orally-disintegrating. After its foundation in 1993, E-Pharma Trento has become an international reference in these technologies by researching, creating and supplying R&D and industrial solutions to pharmaceutical and health…

Interview: Andrew Obenshain – General Manager France & Benelux, Shire

Pharma Interview: Andrew Obenshain – General Manager France & Benelux, Shire

Pharma Shire France’s General Manager, Andrew Obenshain, speaks optimistically about the leading market conditions in France, the corporate culture of a multinational company in a niche market, and building a rapport with government and patients. As an American working in France, what are your key observations about the differences and similarities…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page